To include your compound in the COVID-19 Resource Center, submit it here.

Acceleron reports preliminary Phase II data for ACE-083 in FSHD

Acceleron Pharma Inc. (NASDAQ:XLRN) reported preliminary data from Part 1 of a Phase II trial evaluating ACE-083 to treat facioscapulohumeral muscular dystrophy (FSHD). The company expects to start Part 2

Read the full 305 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE